Keybank National Association OH Trims Stock Position in Zoetis Inc. $ZTS

Keybank National Association OH lessened its stake in Zoetis Inc. (NYSE:ZTS) by 10.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,250 shares of the company’s stock after selling 20,615 shares during the period. Keybank National Association OH’s holdings in Zoetis were worth $26,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in shares of Zoetis in the second quarter valued at approximately $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after acquiring an additional 1,995,491 shares during the period. Corient Private Wealth LLC raised its position in Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. Impax Asset Management Group plc boosted its stake in Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after purchasing an additional 922,589 shares during the period. Finally, Swedbank AB grew its position in Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after purchasing an additional 917,598 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZTS shares. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. dropped their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $152.45.

Zoetis Stock Performance

Shares of ZTS stock opened at $124.79 on Friday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a 50 day simple moving average of $124.08 and a 200-day simple moving average of $137.15. The company has a market cap of $54.99 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 2.10 and a beta of 0.97. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be issued a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.